Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI)
| Autor: | Bhuvaneswari Ramaswamy, Doreen M. Agnese, Maryam B. Lustberg, Stephen P. Povoski, Rachel M. Layman, Xiangyu Yang, D. G. Spigos, Michael V. Knopp, L. A. Houton, Ewa Mrozek |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy Bevacizumab medicine.diagnostic_test business.industry medicine.medical_treatment Magnetic resonance imaging medicine.disease behavioral disciplines and activities Carboplatin chemistry.chemical_compound Dynamic contrast Breast cancer Paclitaxel chemistry Internal medicine medicine Pathologic Response Nuclear medicine business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 28:604-604 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2010.28.15_suppl.604 |
| Popis: | 604 Background: BEV in combination with paclitaxel improves the outcome of previously untreated metastatic BC patients (Miller et al NEJM 357, 2007). We hypothesized that adding BEV to weekly Nab-P... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|